Aptose Biosciences Inc.
APS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.33% | -19.71% | -28.46% | -28.91% | -21.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.37% | -54.27% | -49.85% | -28.51% | -16.46% |
| Operating Income | 47.37% | 54.27% | 49.85% | 28.51% | 16.46% |
| Income Before Tax | 47.58% | 54.78% | 50.34% | 27.31% | 15.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 47.58% | 54.78% | 50.34% | 27.31% | 15.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.58% | 54.78% | 50.34% | 27.31% | 15.32% |
| EBIT | 47.37% | 54.27% | 49.85% | 28.51% | 16.46% |
| EBITDA | 47.32% | 54.24% | 49.83% | 28.46% | 16.41% |
| EPS Basic | 86.57% | 85.06% | 79.58% | 61.05% | 42.14% |
| Normalized Basic EPS | 86.57% | 85.06% | 79.58% | 61.05% | 42.14% |
| EPS Diluted | 86.57% | 85.06% | 79.58% | 61.07% | 42.18% |
| Normalized Diluted EPS | 86.57% | 85.06% | 79.58% | 61.05% | 42.14% |
| Average Basic Shares Outstanding | 339.71% | 299.49% | 214.10% | 124.70% | 78.99% |
| Average Diluted Shares Outstanding | 339.71% | 299.49% | 214.10% | 124.70% | 78.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |